APA (7th ed.) Citation

Lemech, C., Dredge, K., Bampton, D., Hammond, E., Clouston, A., Waterhouse, N. J., . . . Goldstein, D. (2023). Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors. Journal for immunotherapy of cancer, 11(1), e006136. https://doi.org/10.1136/jitc-2022-006136

Chicago Style (17th ed.) Citation

Lemech, Charlotte, et al. "Phase Ib Open-label, Multicenter Study of Pixatimod, an Activator of TLR9, in Combination with Nivolumab in Subjects with Microsatellite-stable Metastatic Colorectal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma and Other Solid Tumors." Journal for Immunotherapy of Cancer 11, no. 1 (2023): e006136. https://doi.org/10.1136/jitc-2022-006136.

MLA (9th ed.) Citation

Lemech, Charlotte, et al. "Phase Ib Open-label, Multicenter Study of Pixatimod, an Activator of TLR9, in Combination with Nivolumab in Subjects with Microsatellite-stable Metastatic Colorectal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma and Other Solid Tumors." Journal for Immunotherapy of Cancer, vol. 11, no. 1, 2023, p. e006136, https://doi.org/10.1136/jitc-2022-006136.